PhoreMost

High-Level Overview

PhoreMost is a drug discovery company specializing in oncology and Targeted Protein Degradation (TPD) therapies, using its proprietary SITESEEKER® platform to identify "undruggable" targets and develop novel degrader therapeutics.[1][2][3][8] It serves pharmaceutical and biotech partners by expanding the druggable proteome through phenotypic screening of protein fragments (PROTEINi®), addressing unmet needs in cancer treatment and protein degradation for diseases like inflammation.[2][4][6] The company solves the challenge of targeting intractable proteins by uncovering cryptic binding sites in live cells, enabling more effective, diverse, and affordable medicines; it has raised significant funding, progressed multiple programs to preclinical stages, and secured partnerships with firms like Boehringer Ingelheim and Sentinel Oncology, with a lead glioma program nearing clinical trials.[1][3][4]

PhoreMost's growth momentum includes a 2018 £11 million Series A led by Cambridge Enterprise Ventures, recent board additions like Chair Barbara Duncan (May 2025), and advancements in GlueSEEKER® for molecular glue discovery, positioning it to unlock new E3 ligases beyond the limited ones (e.g., Cereblon) dominating TPD.[1][3][5]

Origin Story

PhoreMost was founded in 2014 as a spin-out from the University of Cambridge’s MRC Cancer Unit by Professor Ashok Venkitaraman, Dr. Grahame McKenzie, and Dr. Chris Torrance, who brought expertise in cancer biology and drug discovery to tackle "undruggable" diseases.[3][6] The idea emerged from phenotypic screening innovations, evolving the proprietary PROTEINi® technology into SITESEEKER®, a live-cell assay that reveals cryptic druggable sites across the human proteome by testing millions of protein shapes for therapeutic effects.[2][3][6][7]

Early traction came via academic-industrial collaborations and the 2018 Series A funding, which expanded platform capabilities; pivotal moments include partnerships (e.g., Sentinel Oncology for glioma, Oxford Biomedica) and internal pipeline focus on oncology synthetic lethality and TPD, with recent leadership like CEO Neil Torbett driving maturation toward clinical and commercialization stages.[1][3][4][6]

Core Differentiators

PhoreMost stands out in drug discovery through these key strengths:

• SITESEEKER® platform: Next-generation phenotypic screening using diverse PROTEINi® fragments to systematically identify novel, cryptic druggable sites in any disease context, linking them to therapeutic functions in live cells—far beyond traditional methods limited to known pockets.[2][3][6][7][8]
• GlueSEEKER® for TPD innovation: Pioneers mini-protein engineering to discover new E3 ligases (targeting over 600 options vs. industry's few), enabling first-in-class degraders for oncology and inflammation; validates induced protein-protein interactions to overcome molecular glue discovery bottlenecks.[1][5][9]
• Pipeline and partnerships: Internal programs in cancer (e.g., DNA repair synthetic lethality, glioma via Sentinel) advancing to preclinical/clinical; broad alliances with pharma like Boehringer Ingelheim accelerate validation and deal flow.[4][6]
• Wet-lab + AI hybrid: Combines empirical protein fragment libraries with AI guidance for target binding, avoiding AI's limits in undruggable space while rationalizing discovery for speed and diversity.[4][6]

Role in the Broader Tech Landscape

PhoreMost rides the Targeted Protein Degradation (TPD) wave, a transformative modality destroying disease proteins via ubiquitin-proteasome system, expanding "undruggable" targets amid rising cancer resistance to conventional therapies.[1][4][5][6] Timing is ideal as TPD matures—PROTACs enter clinics, but reliance on few ligases creates vulnerabilities; PhoreMost's platforms unlock diverse E3 ligases and glues, fueling a "gold rush" for resistance-proof degraders.[4][5]

Market forces like oncology demand (glioma, synthetic lethality), big pharma's TPD investments, and AI-drug discovery hype favor it, as wet-lab phenotypic approaches complement AI for novel space.[4][6] It influences the ecosystem by partnering to diversify pipelines, rationalizing discovery, and enabling precision medicines for intractable diseases, potentially reshaping 80-90% of the proteome currently undruggable.[3][8]

Quick Take & Future Outlook

PhoreMost is poised for clinical breakthroughs, with its lead glioma program eyeing trials soon, multiple preclinical degraders advancing, and GlueSEEKER® attracting big pharma deals amid TPD's explosive growth.[1][4][5] Trends like ligase diversification, molecular glues, and hybrid AI-wet lab will propel it, evolving its role from target ID to full pipeline commercialization via partnerships and potential IPO.

As a Cambridge pioneer drugging the undruggable, PhoreMost exemplifies how phenotypic innovation meets TPD urgency to deliver tomorrow's oncology therapies.[3][6][8]